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Thymidine phosphorylase (TP) is an enzyme which catalyses two
reactions: (i) the reversible phosphorylation of thymidine to
thymine and 2¢-deoxy-D-ribose-1-phosphate, and (ii) deoxy-
ribosyl transfer between pyrimidines. Overexpression of the
enzyme has been associated with the development of various
cancers (Pauly et al, 1997; Yoshimura et al, 1990). The structure of
human TP is identical (at least in part) to that of platelet-derived
endothelial cell growth factor (PD-ECGF) (Furukawa et al, 1992;
Moghaddam et al, 1992). TP–PD-ECGF has been shown to
possess angiogenic activity in vivo (Ishikawa et al, 1989), and
chemotactic activity in vitro (Haraguchi et al, 1994). The analysis
of mRNA for putative angiogenic factors in ovarian malignancies
revealed the overexpression of TP–PD-ECGF compared with
tissue from benign tumours and the normal ovary (Reynolds et al,
1994). Subsequently, the concentration of TP in ovarian tumour
tissue was shown to be positively correlated with the peak systolic
velocity measured by pulsed-Doppler ultrasound (Hata et al, 1997)
which is an indicator of disordered angiogenesis (Hata et al, 1995).
Although progress has been made in establishing operative
staging of ovarian cancer and defined basic principles of therapy,
there has not been a dramatic change in survival rates since the
1960s (Griffiths and Parker, 1986). The early stages of malignant
growth in the ovary do not usually produce symptoms, and late
diagnosis and ineffective treatments are probably the main reasons
for the poor prognosis. Despite extensive research, the mortality
does not seem to be decreasing (Bourne et al, 1993). However,
even in patients presenting with early disease, an extensive
surgical treatment does not guarantee cure (Scholl et al, 1994).
Therefore, new variables correlating with the malignant potential
of the cancer cells would be clinically valuable in adjuvant therapy
for individual patients in early stage ovarian cancer. Biological
factors that regulate the growth of this disease are poorly defined.
Recently, there have been studies on the correlation between the
expression of TP by immunohistochemical analysis, and invasive-
ness and progression of tumours in breast (Fox et al, 1996), lung
(Giatromanolaki et al, 1997), gastric (Maeda et al, 1996), colon
(Takebayashi et al, 1996) and bladder cancers (O’Brien et al,
1996). Potential for its clinical relevance has been reported;
however, the results differ among each cancer (Fox et al, 1996;
Maeda et al, 1996; O’Brien et al, 1996; Takebayashi et al, 1996;
Giatromanolaki et al, 1997).
In the present study, we have examined mRNA expression of
the TP using reverse transcriptase polymerase chain reaction
(RT-PCR) in 56 epithelial ovarian cancers. The expression of this
enzyme has been related to clinical and pathological parameters
to evaluate further the role of TP in epithelial ovarian cancer.
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Summary Thymidine phosphorylase (TP) is associated with angiogenesis and the progression of solid tumours. High intracellular levels of
this enzyme indicate increased chemosensitivity to pyrimidine antimetabolites. TP gene expression in 56 cases of epithelial ovarian cancer
(27 of serous, 10 mucinous, 12 endometrioid, five clear cell and two undifferentiated) were analysed by polymerase chain reaction of RNA
after reverse transcription. These included eight of low malignant potential. Twenty were stage I, four stage II, 27 stage III and five stage IV.
The level of TP gene expression was presented by the relative yield of the TP gene to the b2-microglobulin gene. TP gene expression ranged
from 0.19 to 5.38 (median 0.93). The value of TP gene expression in stage III–IV was significantly higher than that of TP gene expression in
stage I–II (P = 0.0005). Histological grade significantly associated with TP gene expression (P = 0.008), but histological subtype did not
(P = 0.166). A follow-up study of 34 cases after complete resection of the primary tumours by surgical operation was performed. TP gene
expression of the cases with recurrence showed significantly higher levels compared to cases without recurrence (P = 0.049). Survival data
were available for 47 of the 56 patients. The prognosis of the patients with high TP gene expression (equal to, or greater than, median) was
to be significantly worse than patients with low TP gene expression (less than median) (P = 0.021). The TP gene expression level may play
one of the key roles in the biology of ovarian epithelial cancer and define a more aggressive tumour phenotype. A new therapeutic
intervention mediated by TP protein activity is anticipated.
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MATERIALS AND METHODS
Patients
A total of 56 patients (aged 19–76 years, mean 50 years) with
histologically confirmed primary epithelial ovarian cancer were
studied (Table 1). No patient received any therapy before surgery.
The patients were staged according to criteria recommended by
the International Federation of Obstetricians and Gynecologists
(FIGO) criteria (1987). The staging system defined by FIGO
assumes that an adequate staging operation has been performed
(Cannistra, 1993). The staging operation included collection of
ascites or peritoneal washing from the pelvis, gutters and
diaphragms for cytological studies; total abdominal hysterectomy
with bilateral salpingoophorectomy; infracolic omentectomy and
appendectomy; selective pelvic and para-aortic lymphadenec-
tomy; and debulking of all gross diseases. If obvious macroscopic
tumour was not present, the following were performed: biopsy of
any lesion suspect for tumour metastasis or any adhesion adjacent
to the primary tumour; blind biopsy of bladder peritoneum and
cul-de-sac, right and left paracolic gutter and pelvic side walls;
biopsy or smear of right hemidiaphragm. Survival data were avail-
able for 47 of the 56 patients (median 36 months, range 2–120
months). Of these, 45 patients received cisplatin-containing regi-
mens. Two stage I tumours of low malignant potential received no
further treatment after surgery.
Tissue specimen and RNA preparation
Fresh surgical specimens from all patients were obtained, and the
tissues for investigation were prepared carefully under a dissecting
microscope to eliminate inappropriate components. Moreover, one
stage I epithelial ovarian cancer (serous cystadenocarcinoma) with
primary colorectal cancer that resulted in death 2 months after
operation and benign ovarian tumour tissues (serous cystadenoma,
fibroma) were dissected. The tissue samples were stored at –80°C
for subsequent analysis. Normal liver tissues were used as positive
control for TP gene expression. As negative control for TP gene
expression, breast carcinoma cell line MCF-7 was kindly provided
by Dr Akira Yamauchi.
Table 1 Thymidine phosphorylase gene expression in each ovarian cancer
Case Age Stage Histology Histological TP gene Case Age Stage Histology Histological TP gene
(years) gradea expression (years) gradea expression
1 28 I Serous 1 1.33 29 61 I Mucinous 1 0.41
2 56 I Serous 1 0.25 30 26 I Mucinous 1 0.40
3 42 I Serous 1 0.94 31 53 I Mucinous 2 1.41
4 54 II Serous 2 0.20 32 58 I Mucinous 1 0.61
5 58 III Serous 3 2.08 33 47 I Mucinous 4 1.79
6 48 III Serous 3 0.71 34 38 I Mucinous 1 0.44
7 58 III Serous 4 2.48 35 46 III Mucinous 3 0.37
8 58 III Serous 3 1.30 36 42 III Mucinous 2 0.36
9 63 III Serous 4 5.38 37 47 IV Mucinous 4 3.21
10 24 III Serous 2 0.55 38 60 I Endometrioid 3 0.25
11 40 III Serous 3 2.46 39 45 I Endometrioid 3 0.24
12 61 III Serous 2 0.82 40 51 I Endometrioid 4 0.44
13 66 III Serous 3 4.47 41 60 I Endometrioid 2 0.42
14 56 III Serous ND 0.35 42 43 I Endometrioid 3 1.65
15 63 III Serous 2 0.28 43 38 I Endometrioid 4 1.14
16 46 III Serous 4 0.30 44 70 II Endometrioid 3 0.22
17 54 III Serous 2 0.19 45 54 II Endometrioid 3 1.08
18 57 III Serous 4 2.08 46 46 III Endometrioid 4 3.37
19 67 III Serous 4 0.80 47 49 III Endometrioid 4 0.25
20 48 III Serous 3 5.10 48 37 III Endometrioid 3 1.44
21 53 III Serous 3 2.10 49 45 III Endometrioid 3 1.83
22 49 III Serous 2 1.10 50 52 I Clear cell 4 1.21
23 55 III Serous 3 2.80 51 47 I Clear cell 3 0.56
24 30 IV Serous 3 0.92 52 40 I Clear cell 2 0.48
25 62 IV Serous 4 0.97 53 60 I Clear cell 3 2.80
26 33 IV Serous 4 2.82 54 47 II Clear cell ND 0.65
27 19 IV Serous 3 2.73 55 48 III Undifferentiated 4 4.70
28 55 I Mucinous 1 0.29 56 76 III Undifferentiated 4 0.71
a1, low malignant potential; 2, well differentiated; 3, moderately differentiated; 4, poorly differentiated; ND, not determined
TP
b2-MG
123456789
– 152 bp
– 120 bp
Figure 1 The representative thymidine phosphorylase (TP) gene
expression by RT-PCR (b2-MG: b2-microglobulin, lane 1; ovarian cancer
stage I, lane 2; ovarian cancer (serous cystadenocarcinoma) stage I with
primary colorectal cancer which resulted in death 2 months after operation,
lane 3; ovarian cancer stage II, lane 4; ovarian cancer stage III, lane 5;
ovarian cancer stage IV, lanes 6 and 7; benign ovarian tumour, lane 8; MCF-
7, lane 9; normal liver)1850 K Hata et al
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Figure 2 Thymidine phosphorylase (TP) gene expression in stage I–II and III–IV. Horizontal line indicates the median value
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Figure 3 Thymidine phosphorylase (TP) gene expression in relation to histological grades (1, low malignant potential; 2, well differentiated; 3, moderately
differentiated; 4, poorly defferentiated). Horizontal line indicates the median valueThymidine phosphorylase in epithelial ovarian cancer 1851
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RT-PCR
RT-PCR for determination of TP gene expression was performed
according to the method previously described (Arao et al, 1994).
Briefly, complementary DNA (cDNA) was prepared by random
priming from 500 ng of total RNA using a First-Strand cDNA
Synthesis kit (Pharmacia-LKB, Uppsala, Sweden). Pairs of
oligonucleotide primers for PCR were designed to insert an intron
in the corresponding genomic sequence to eliminate amplification
from genomic DNA. Primers for TP gene amplification is
TGGCTCAGTCGGGACAGCAG (upstream) and TCCGCTGAT-
CATTGGCACCT (downstream), and the PCR product is 152 bp
(Hagiwara et al, 1991). The PCR was carried out in a Thermal
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Figure 4 Thymidine phosphorylase (TP) gene expression in relation to histological subtypes. Horizontal line indicates the median value
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Figure 5 Thymidine phosphorylase (TP) gene expression in patients with recurrence and without recurrence after complete resection. Horizontal line indicates
the median valueCycler (Perkin-Elmer Cetus, Northwalk, CT, USA) with a mixture
consisting of cDNA derived from 5 ng of RNA, 10 pmol of
upstream and downstream primers for the sequences of the TP
gene and 5 pmol of primers for the b2-microglobulin (b2-MG)
gene, 200 mmol of deoxynucleotide triphosphate, 37 kBq of [a-
32P] dCTP, and 0.1 unit of Taq DNA polymerase with reaction
buffer (Life Technologies, Rockville, MD, USA) in a final volume
of 10 ml. The condition for PCR was denaturation at 94°C for 1
min, annealing at 58°C for 1 min and extension at 72°C for 1 min.
Thirty cycles of PCR were performed for each specimen, and the
products were separated on 9% polyacrylamide gels. Then
radioactivity was determined by BAS 2000 Bioimage Analyzer
(Fujix, Tokyo, Japan). The TP expression was presented by the
relative yield of the TP gene to that of the b2-MG gene.
Histological grading
Histologically we classified tumours into four grades including a
non-invasive grade as previously described (Arao et al, 1994). The
brief concept of grading used in the present study is as follows. A
tumour of grade 1 is low malignant potential (LMP), which is non-
invasive to surrounding tissues. Tumours of grade 2–4 correspond
to well differentiated, moderately differentiated and poorly differ-
entiated carcinoma respectively.
Statistical analysis
Mann–Whitney U-test and Kruskal–Wallis one-way analysis of
variance by ranks were used as appropriate for the evaluation of
significant differences between end-points. Survival curves were
calculated using the Kaplan–Meier method and analysed by the
log-rank test. Factors significantly related to survival in the log-
rank test were analysed by Cox’s proportional hazard model with a
stepwise regression analysis (Cox, 1972). A P-value < 0.05 was
considered to be statistically significant.
RESULTS
RT-PCR and TP gene expression
To determine the number of PCR cycles appropriate for quantifi-
cation, PCR was performed from 20 to 50 cycles at increase of
5 cycles. The expression ratios of TP to b2-MG were reasonably
constant from 25 to 40 cycles (data not shown). Therefore, in the
subsequent experiments, the values at 30 PCR cycles were defined
as the expression of target genes. The representative profile of
TP gene expression by RT-PCR is shown in Figure 1.
TP gene expression and clinicopathological features
TP gene expression in ovarian cancer tissues is summarized in
Table 1 (median 0.93, range 0.19–5.38). The numbers of gene
expression are mean values from at least three independent
RT-PCR experiments. The value of TP gene expression in stage
III–IV (median 1.64, range 0.19–5.38) was significantly higher
than that in stage I–II (median 0.46, range 0.20–1.79) (P = 0.0005)
(Figure 2). Histological grade significantly associated with TP
gene expression (P = 0.008) (Figure 3); however, histological
subtype did not (P = 0.166) (Figure 4).
TP gene expression and prognosis
A follow-up study of 34 cases after complete resection of the
primary tumours by surgical operation. TP gene expression of the
eight cases with recurrence (median 1.95, range 0.28–5.10)
showed significantly higher levels compared to that of 26 cases
without recurrence (median 0.66, range 0.20–2.10) (Figure 5).
Survival data were available for 47 of the 56 patients. As shown in
Figure 6, we found the prognosis of the patients with high TP gene
expression equal to, or greater than, median to be significantly
worse than that of those with low TP gene expression less than
median by log-rank test (P = 0.021). Moreover, FIGO stage
(III–IV) (P = 0.001), residual disease (> 2 cm) (P = 0.006) and
histological grade (poorly differentiated) (P = 0.048) were found
to be significantly associated with worse prognosis in univariate
analysis (Table 2). Multivariate analysis of survival using Cox’s
proportional hazard model revealed that FIGO stage (III–IV) is an
independent prognostic factor (P = 0.041) (Table 3).
DISCUSSION
In spite of significant advances in surgery and the use of new, more
effective chemotherapuetic regimens, the overall 5-year survival
of patients with ovarian cancer is about 30%. Multivariate analysis
of 21 240 cases of primary ovarian epithelial cancer showed that
stage, histology, grade, age, the presence of ascites, lymph node
status and race are all predictors of survival (Kosary, 1994).
Identification of new prognostic factors might be of value in
directing therapy and intensifying follow-up for a select group of
patients.
The advent and development of PCR, a highly sensitive and
efficient method of amplifying specific DNA segments present
at low concentrations, provides an alternative approach for
estimating the relative gene expression in small amount of tissues
(Eisenstein, 1990). By amplifying cDNA reverse transcribed from
RNA, the PCR can be used to measure quantitative expression of
specific genes in tumour cells (Arao et al, 1994). While gene
expression is not a direct measure of enzyme activity, Mimori et al
(1997) reported that there is a significant correlation between TP
enzyme activity and TP mRNA expression measured by RT-PCR.
This is the first study on TP gene expression determined by
RT-PCR in epithelial ovarian cancers. TP gene expression in
stage III–IV was significantly higher compared with stage I–II.
Moreover, TP gene expression was significantly associated with
histological grades. TP gene expression of the cases with recur-
rence showed significantly higher levels compared to those
without recurrence. Elevated TP gene expression is significantly
correlated with reduced survival when examined by univariate
analysis. Multivariate analysis, however, demonstrated that TP
gene expression is not an independent prognostic factor among the
clinicopathological parameters studied. It has to be noted that the
number of cases was limited. This molecular evaluation indicates
that TP gene expression level may play one of the key roles in the
biology of ovarian epithelial cancer and define a more aggressive
tumour phenotype. Lane 2 in Figure 1 presents the results of
RT-PCR in patient of stage I (serous cystadenocarcinoma) with
primary colorectal cancer who died 2 months after operation. The
TP gene expression was remarkably high at 4.77. The TP gene
expression in this primary ovarian cancer tissue might reflect its
poor prognosis, although the clinical stage of ovarian cancer was
early.
1852 K Hata et al
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The amino acid sequence for TP does not encode a signal
peptide, and TP is not a classic paracrine growth factor in this
regard (Miyadera et al, 1995). It is suggested that 2¢-deoxy-D-
ribose-1-phosphate, the catalytic product of thymidine by TP, is
responsible for various biological activities of TP (Haraguchi et al,
1994). It is also possible that TP is released by a non-classical
pathway. TP positivity assessed by immunohistochemistry is
associated with microvessel count and prognosis in various
cancers (Maeda et al, 1996; O’Brien et al, 1996; Takebayashi et al,
1996; Giatromanolaki et al, 1997). However, TP expression is an
independent prognostic factor even after adjustment for
microvessel count in tumour tissues (Takebayashi et al, 1996). TP
may have effects other than angiogenic activity concerned with the
tumour progression. Recently, Takebayashi et al (1997) reported
that TP is induced by hypoxia in KB 3-1 cells that have no endo-
genous TP activity and that hypoxia-resistant subclone
KB-HR3 cells express TP. Furthermore, KPE-3 cells which are
transfected with TP cDNA are resistant to apoptosis induced by
hypoxia (Takebayashi et al, 1997). These results indicate that
the hypoxia-mediated TP gene induction and selection of TP-
expressing cells play an important role in progression of many
solid tumours. Further study is needed to assess how TP gene
expression is associated with unfavourable prognosis of ovarian
epithelial cancer.
TP catalyses formation of 5-fluorouracil (5-FU) from its
prodrug, 5¢-deoxy-5-fluorouridine (5¢-DFUR) (Kono et al, 1983).
Furthermore, toxicity of the active drug 5-FU may be enhanced
by changing into 5-fluoro-2¢-deoxyuridine through transfer of 2¢-
deoxy-D-ribose-1-phosphate. These pyrimidine antagonists can
ultimately inhibit the synthesis of DNA (Zimmerman and
Seidenberg, 1964). It has also been reported that 5-FU can induce
apoptosis in some cancer cells (Szepeshazi et al, 1991). Increased
sensitivity to 5¢-DFUR has been demonstrated in vitro by transfec-
tion of the TP gene into the MCF-7 breast carcinoma cell line
(Patterson et al, 1995). Elevated expression of TP in tumour cells
suggests that 5¢-DFUR would be differentially activated in tumour
cells (O’Brien et al, 1996). It is noted that preoperative
chemotherapy with 5¢-DFUR is useful for reducing minute cancer
foci and microscopic metastatic lesions in gastric cancer (Kumagai
et al, 1993). Consequently, it is possible that treatment with
5¢-DFUR might be highly selective for the inhibition of tumour
progression in epithelial ovarian cancer with high TP gene expres-
sion. Assessment of TP gene expression should be taken into
account of randomized trial evaluating the role of adjuvant
chemotherapy in epithelial ovarian cancer.
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Figure 6 Comparison of survival between groups with high thymidine phosphorylase (TP) gene expression (n n; ³ 0.93; n = 25) and low TP gene expression (l l
< 0.93; n = 22) according to the Kaplan–Meier method
Table 2 Univariate analysis of survival using the log-rank test
Variables P-value
FIGO stage 0.001
I–II (n = 22) vs III–IV (n = 25)
Residual disease 0.006
≤ 2 cm (n = 34) vs > 2 cm (n = 13)
Histology 0.647
Serous (n = 21) vs others (n = 26)
Grade 0.048
Others (n = 34) vs poorly (n = 13)
TP gene expression 0.021
< 0.93 (n = 22) vs ³ 0.93 (n = 25)
TP, thymidine phosphorylase.
Table 3 Multivariate analysis of survival using Cox’s proportional hazard
model
Variables Hazard ratio 95% CI P-value
FIGO stage 4.19 1.1–130.4 0.04
I–II (n = 22) vs III–IV (n = 25)
Residual disease 1.15 0.6–6.5 0.284
≤ 2 cm (n = 34) vs > 2 cm (n = 13)
Grade 3.00 0.8–7.9 0.083
Others (n = 34) vs poorly (n = 13)
TP gene expression 0.91 0.5–13.8 0.34
< 0.93 (n = 22) vs ³ 0.93 (n = 25)
TP, thymidine phosphorylase.1854 K Hata et al
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